Comprehensive clinical characterization of patients with BRCA1: c.5017_5019del germline variant

• Published in: Annals of surgical treatment and research 2022-12, Vol.103 (6), p.323-330
• Main Authors: Bang, Yoon Ju, Kwon, Won Kyung, Kim, Jong-Won, Lee, Jeong Eon, Jung, Boo Yeon, Kim, Mina, Kim, Jisun, An, Jeongshin, Jung, Seung Pil, Kim, Hong-Kyu, Kim, Zisun, Youn, Hyun Jo, Ryu, Jai Min, Kim, Sung-Won
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2288-6575; 2288-6796
• DOI: 10.4174/astr.2022.103.6.323

We provide evidence for the reclassification of the :c.5017_5019del variant by presenting the clinicopathological characteristics, clinical outcomes, and family history of breast or ovarian cancer in 17 patients with this variant. This study included breast or ovarian cancer patients tested for genes between January 2008 and June 2020 at 10 medical centers in Korea. We retrospectively reviewed 17 probands from 15 families who had the :c.5017_5019del variant according to the electronic medical records. We present 10 breast cancer patients and 7 ovarian cancer patients from 15 families identified as having :c.5017_5019del and a total of 19 cases of breast cancer and 14 cases of ovarian cancer in these families. The ratio of breast-to-ovarian cancer was 1.3:1. Breast cancer patients with this variant showed a rich family history of breast or ovarian cancer, 8 patients (80.0%). The mean age at diagnosis was 45.4 years and 6 patients (60.0%) were categorized into hormone-receptor-negative breast cancer. Also, the ovarian cancer patients with this variant showed strong family histories of breast and/or ovarian cancer in 4 patients (57.1%). We presented clinical evidence for the reclassification of :c.5017_5019del as a likely pathogenic variant (LPV). Reclassification as LPV could result in the prophylactic treatment and medical surveillance of probands, family testing recommendations, and appropriate genetic counseling of their families.